An NHS manager joined a work call with Nazi paraphernalia on display in the background and they reportedly still have their ...

Disclaimer: The views and investment tips by experts in this News18.com report are their own and not those of the website or its management. Users are advised to check with certified experts before ...

Shares of CIE Automotive India Ltd., Muthoot Finance Ltd., Ami Organics Ltd. and Sanofi India Ltd. will trade ex/record-date for their corporate actions this week. CIE Automotive will record its ...

All the news that moves the needle in pharma and biotech Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters. Receive The Pharma ...

Paris: Sanofi and Regeneron Pharma have received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older ...

Ranjeet Mechatronics Split: Ranjeet Mechatronics is also set for Rs 10-to-Rs 5 stock split on April 21, 2025. Sanofi India Dividend: The pharma firm declared a final dividend of Rs 117 per equity ...

- 10,000 Pref. and 10,000 No. of Equity shares of Rs 100 each issued to promoters. 5000 Pref. and 9,867 No. of Equity shares as Rights in proportion to holdings.

Regeneron Pharmaceuticals and Sanofi won U.S. Food and Drug Administration expanded approval of their blockbuster anti-inflammatory drug Dupixent for the inflammatory skin condition chronic ...

A close look shows that Eugenie chose a sentimental shot for her lock screen Janine Henni is a Royals Staff Writer for PEOPLE Digital, covering modern monarchies and the world's most famous ...

Regeneron and Sanofi are committed to helping patients in the U.S. who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT Dupixent has ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent has experienced few setbacks. One came in 2023, however, when the FDA ...